A detailed history of Creative Planning transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Creative Planning holds 49,347 shares of BCRX stock, worth $380,958. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,347
Previous 46,613 5.87%
Holding current value
$380,958
Previous $288,000 30.21%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$6.41 - $8.69 $17,524 - $23,758
2,734 Added 5.87%
49,347 $375,000
Q2 2024

Aug 15, 2024

BUY
$4.13 - $6.79 $82,657 - $135,895
20,014 Added 75.24%
46,613 $288,000
Q1 2024

May 10, 2024

BUY
$4.89 - $7.65 $63,506 - $99,350
12,987 Added 95.41%
26,599 $135,000
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $67,787 - $92,153
13,612 New
13,612 $81,000
Q2 2021

Aug 04, 2021

SELL
$9.5 - $17.24 $175,360 - $318,233
-18,459 Closed
0 $0
Q1 2021

Apr 30, 2021

BUY
$7.37 - $13.61 $136,042 - $251,226
18,459 New
18,459 $188,000
Q2 2018

Jul 20, 2018

SELL
$4.6 - $6.52 $84,410 - $119,641
-18,350 Closed
0 $0
Q1 2018

Apr 18, 2018

BUY
$4.35 - $5.82 $79,822 - $106,797
18,350 New
18,350 $88,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.44B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.